tazobactam has been researched along with mocetinostat in 1 studies
| Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (mocetinostat) | Trials (mocetinostat) | Recent Studies (post-2010) (mocetinostat) |
|---|---|---|---|---|---|
| 1,327 | 153 | 694 | 21,735 | 390 | 8,606 |
| Protein | Taxonomy | tazobactam (IC50) | mocetinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.7851 | |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | 0.022 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.57 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.102 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.102 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.3433 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.3537 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.6386 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.6725 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.045 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyama, K; Hamaoka, S; Katoh, H; Kinoshita, M; Naito, Y; Sawa, T; Shimizu, M | 1 |
1 other study(ies) available for tazobactam and mocetinostat
| Article | Year |
|---|---|
Protective effects of intravenous immunoglobulin and antimicrobial agents on acute pneumonia in leukopenic mice.
Topics: Animals; Anti-Bacterial Agents; Body Temperature; Colistin; Cytokines; Edema; Immunoglobulin G; Immunoglobulins, Intravenous; Leukopenia; Lung; Male; Mice; Mice, Inbred ICR; Penicillanic Acid; Peroxidase; Piperacillin; Pneumonia, Bacterial; Pre-Exposure Prophylaxis; Protective Agents; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |